These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 11911507)

  • 21. Sequencing of hormonal therapy in breast cancer.
    Ingle JN
    Breast J; 2002; 8(6):332-7. PubMed ID: 12390355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal adjuvant endocrine therapy for early breast cancer.
    Stuart-Harris R; Davis A
    Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anastrozole: a new addition to the armamentarium against advanced breast cancer.
    Buzdar AU
    Am J Clin Oncol; 1998 Apr; 21(2):161-6. PubMed ID: 9537204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Bao T; Davidson NE
    Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecularly targeted endocrine therapies for breast cancer.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Rizzo P; Marino A; D'Amico M; Sponziello F; Mazzoni E; Cinefra M; Fazio N; Maiello E; Silvestris N; Colucci G; Cinieri S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S67-71. PubMed ID: 21129614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
    Santen RJ
    J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
    Rose C; Kamby C; Mouridsen HT; Andersson M; Bastholt L; Møller KA; Andersen J; Munkholm P; Dombernowsky P; Christensen IJ
    Breast Cancer Res Treat; 2000 May; 61(2):103-10. PubMed ID: 10942095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antiestrogen therapy in the treatment of breast neoplasms].
    Alba E; Ragonesi G; Colla F; Mazzoleni A; Farina C
    Minerva Ginecol; 2002 Jun; 54(3):245-51. PubMed ID: 12063440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of endocrine options for the treatment of advanced breast cancer.
    Kaufmann M
    Oncology; 1997; 54 Suppl 2():2-5. PubMed ID: 9394852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
    Higa GM
    Expert Opin Pharmacother; 2001 Jun; 2(6):987-95. PubMed ID: 11585014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on endocrine therapy for breast cancer.
    Buzdar AU; Hortobagyi G
    Clin Cancer Res; 1998 Mar; 4(3):527-34. PubMed ID: 9533518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of aromatase inhibitors in the treatment of breast cancer.
    Choueiri TK; Alemany CA; Abou-Jawde RM; Budd GT
    Clin Ther; 2004 Aug; 26(8):1199-214. PubMed ID: 15476902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
    Buzdar AU; Vergote I; Sainsbury R
    Breast J; 2004; 10(3):211-7. PubMed ID: 15125747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolving uses of hormonal agents for breast cancer therapy.
    Cummings FJ
    Clin Ther; 2002; 24 Suppl C():C3-25. PubMed ID: 12117074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
    Fentiman IS
    Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine therapy of breast cancer.
    Lumachi F; Luisetto G; Basso SM; Basso U; Brunello A; Camozzi V
    Curr Med Chem; 2011; 18(4):513-22. PubMed ID: 21143113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.